Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic ...

Biopharmaceutical company Akebia Therapeutics (NASDAQ:AKBA) is emerging as a remarkable opportunity for investors looking to delve into the healthcare sector. The stock is up 271.03% (YoY ...

Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic ...

Vafseo's strong US launch and outperforming Q1 revenues signal robust demand and even potential for eventual blockbuster status, but near-term profitability remains uncertain. Auryxia's patent ...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity ...

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is ...

Akebia Therapeutics, Inc. announced the publication of pre-specified analyses from its global phase 3 clinical trials of vadadustat for treating anemia in chronic kidney disease (CKD) in the ...

CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...

CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...